NCT06563895: An ongoing trial by Eidos Therapeutics, a BridgeBio company
This trial is ongoing. It must report results 6 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06563895 |
|---|---|
| Title | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 12, 2025 |
| Completion date | Oct. 31, 2031 |
| Required reporting date | Oct. 30, 2032, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |